Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Ex Vivo Selective Depletion of Alloreactive Donor T-Lymphocytes Using "RFT5-SMPT-dgA": Reducing GVHD Risk Associated With Matched, Nonmyeloablative, Stem Cell Transplant for Hematologic Malignancies in Older Adults

NCT00025662 is registered in ClinicalTrials.gov with National Heart, Lung, and Blood Institute (NHLBI) as lead sponsor.

NCT NCT00025662
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00025662 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Ex Vivo Selective Depletion of Alloreactive Donor T-Lymphocytes Using "RFT5-SMPT-dgA": Reducing GVHD Risk Associated With Matched, Nonmyeloablative, Stem Cell Transplant for Hematologic Malignancies in Older Adults
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
Phase
Phase 2
Overall status
Completed
Start date
May 31, 2001
Completion date
February 29, 2008
Enrollment
23 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

graft vs host disease, hodgkin disease, leukemia, leukemia, lymphocytic, leukemia, myeloid, leukemia, myelomonocytic, chronic, lymphoma, lymphoma, mantle-cell, lymphoma, non-hodgkin, myelodysplastic syndromes